Skip to content

Prevention Strategy for Post-ERCP Cognitive Dysfunction (POCD) Based on Traditional Chinese Medicine Theory: Application and Management of Transcutaneous Electrical Acupoint Stimulation (TEAS)

Prevention Strategy for Post-ERCP Cognitive Dysfunction (POCD) Based on Traditional Chinese Medicine Theory: Application and Management of Transcutaneous Electrical Acupoint Stimulation (TEAS)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025000996
Enrollment
Unknown
Registered
2025-05-15
Start date
2025-07-01
Completion date
Unknown
Last updated
2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Cognitive Dysfunction (POCD) following Endoscopic Retrograde Cholangiopancreatography (ERCP)

Interventions

Intervention group:TEAS Treatment
-Control Group:sham TEAS treatment(non-acupoint electrode placement with no electrical stimulation delivered)

Sponsors

Xinxiang Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) Aged 18–65 years with a BMI of 18.5–27.9 kg/m² and eligible for ERCP (endoscopic retrograde cholangiopancreatography); (2) American Society of Anesthesiologists (ASA) Physical Status Class I to III; (3) No history of drug allergies or contraindications to related medications.

Exclusion criteria

Exclusion criteria: (1) Preoperative cognitive impairment or abnormal scores on the Mini-Mental State Examination (MMSE <24) or Montreal Cognitive Assessment (MoCA <26); (2) Significant impairment of cardiac pulmonary hepatic or renal function; (3) History of traumatic brain injury neurological disorders or alcohol abuse; (4) Inability to communicate effectively with healthcare providers or cooperate in completing cognitive function assessments.

Design outcomes

Primary

MeasureTime frame
Incidence of postoperative cognitive dysfunction (POCD);

Secondary

MeasureTime frame
neurofilament light chain protein (NfL); BDNF;S100ß protein;

Countries

China

Contacts

Public ContactZhaolifang

Xinxiang Central Hospital

zhaolifanggong@sina.cn17637306376

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026